Background A retrospective analysis verified the role of gene mutations in brain metastasis
in patients with non‐small cell lung cancer (NSCLC). Methods Data from 552 patients with …

Tyrosine kinase domains dynamically fluctuate between two main structural forms that are
referred to as type I (DFG-in) or type II (DFG-out) conformations. Comprehensive data …

Objectives The oncogenic MET exon 14 skipping mutation (METex14del) is described to
drive 1.3%–5.7% of non-small-cell lung cancer (NSCLC) and multiple studies with cMET …

The identification of driver mutations in epidermal growth factor receptor, anaplastic
lymphoma kinase, the BRAF and ROS1 genes and subsequent successful clinical …

Cardiovascular diseases may determine therapy outcomes of non-small-cell lung cancer
(NSCLC). The evidence for how iatrogenic cardiovascular complications contribute to …

Although immunotherapies have achieved remarkable salutary effects among subgroups of
advanced cancers, most patients do not respond. We comprehensively evaluated …

Bone metastasis (BM) in cancer remains a critical issue because of its associated clinical
and biological complications. Moreover, BM can alter the quality of life and survival rate of …

The treatment for anaplastic lymphoma kinase (ALK)‐positive lung cancer has been rapidly
evolving since the introduction of several ALK tyrosine kinase inhibitors (ALK‐TKI) in clinical …

Pyrazole being a heterocyclic motif has secured an eccentric status in the field of medicinal
chemistry. Pyrazole and its derivatives have tremendous biological applications like anti …

Non-small-cell lung cancer (NSCLC), a main subtype of lung cancer, is one of the most
common causes of cancer death in men and women worldwide. Circulating tumor DNA …